Overview

Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)

Status:
Completed

Trial end date:
2009-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to: 1. determine the American College of Rheumatology (ACR) 20 response rate at Day 85 in subjects with active rheumatoid arthritis(RA) administered MDX 1100 with methotrexate (MTX); and 2. determine the tolerability and safety of multiple doses of MDX-1100 in combination with MTX in subjects with active RA.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Antibodies
Antibodies, Monoclonal
Methotrexate